Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Top twenty single nucleotide polymorphisms (SNPs) that showed the strongest heterogeneity in association between never hormone therapy users (N = 1,008) and postmenopausal current estrogen and progestin users (N = 248), by P for interaction.

From: Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users

Gene SNP SNPs per gene Alleles WW WV+VV Beta SE P1 Pb2 Pint3
PRL rs10946545 34 G/A 219 29 10.86 3.04 0.0004 0.0144 0.0008
ESR2 rs12434245 29 C/T 216 32 -8.09 2.94 0.0063 0.1839 0.0034
TNF rs3093553 15 T/G 228 20 -9.86 3.63 0.0070 0.1050 0.0046
CYP1A1/CYP1A2 rs3743 13 G/C 233 15 -9.79 4.16 0.0194 0.2524 0.0061
TNF rs3093662 15 A/G 225 23 -8.53 3.42 0.0133 0.2002 0.0064
TNF rs4947324 15 C/T 214 34 -8.53 2.89 0.0035 0.0520 0.0154
PRL rs2744117 34 G/T 212 36 7.97 2.80 0.0048 0.1633 0.0206
ESR2 rs7159462 29 C/T 214 34 -6.61 2.87 0.0222 0.6447 0.0248
PRL rs1156546 34 A/C 163 85 4.77 2.09 0.0230 0.7812 0.0249
SHBG rs6258 13 C/T 246 2 23.25 11.09 0.0370 0.4815 0.0345
ESR2 rs10137185 29 C/T 209 39 -5.20 2.73 0.0575 1.6684 0.0425
PGR rs569857 32 T/A 217 31 -5.69 3.02 0.0603 1.9306 0.0434
PPARG rs4279078 32 G/A 203 45 6.09 2.58 0.0190 0.6082 0.0442
PPARG rs2960420 32 C/G 111 137 -4.60 1.99 0.0219 0.6997 0.0458
VEGF rs699946 21 A/G 159 89 -3.96 2.08 0.0587 1.2333 0.0719
PGR rs7106686 32 G/A 188 60 -4.46 2.32 0.0559 1.7873 0.0854
PRL rs9358533 34 C/T 207 41 6.45 2.66 0.0159 0.5413 0.0927
PGR rs507141 32 G/A 185 63 4.40 2.28 0.0550 1.7594 0.1431
PGR rs5181 32 C/G 208 40 -5.58 2.72 0.0411 1.3164 0.1753
PRL rs1205960 34 C/T 140 108 -3.86 2.01 0.0559 1.8994 0.1765
  1. 1From linear regression models using percent mammographic density as the outcome variable. Adjusted for age and BMI in a dominant model of inheritance. 2Bonferroni-adjusted P values. 3P for interaction for EPT vs. never HT users in all postmenopausal women (N = 2,036).